---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-016912"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:24:01.994422+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q1 net loss $1.4M; guides FY26 product revenue at least $10.5M

## Summary
- Q1 product revenue $2.9M (down 12% YoY, but up 5.5% sequentially from Q4 FY25).
- Net loss $1.4M ($0.03/sh) vs net income $1.8M ($0.06/sh) in Q1 FY25 due to no license revenue.
- Cash $3.6M as of Dec 31, 2025; funded through FY26 if milestones hit.
- Completed 9 trigeminal neuralgia cases after FDA clearance; all patients reportedly pain free.
- Expects FY26 product revenue of at least $10.5M, a 17% YoY increase from $9.1M.

## SEC filing metadata
- accession: 0001213900-26-016912
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390026016912/0001213900-26-016912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390026016912/ea0277131-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-016912
- JSON: https://secwatch.observer/filing/0001213900-26-016912.json
- Plain text: https://secwatch.observer/filing/0001213900-26-016912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.